Nexus Finance
AAKG.DE ARK Genomic Revolution UCITS ETF | IE000O5M6XO1

TER

0.75%

Total Expense Ratio per year

Fund Size

$87627.16B

Assets under management

Holdings

32

Underlying equities

Dividend Yield

N/A

Accumulating

Performance Analysis

Based on selected timeframe (1D)

Top Performers - Upside

Ionis Pharmaceuticals, Inc. IONS
+1.22%
Eli Lilly and Company LLY
+0.86%
908 Devices Inc. MASS
+0.42%

Top Performers - Downside

Tempus AI, Inc. TEM
-7.22%
GeneDx Holdings Corp. WGS
-6.75%
Absci Corporation ABSI
-6.32%

Top Contributors - Upside

Eli Lilly and Company LLY • Weight: 4.81% • Perf: +0.86%
+0.04% Impact
Ionis Pharmaceuticals, Inc. IONS • Weight: 1.64% • Perf: +1.22%
+0.02% Impact
908 Devices Inc. MASS • Weight: 0.99% • Perf: +0.42%
+0.00% Impact

Top Contributors - Downside

Tempus AI, Inc. Weight: 7.50% • Perf: -7.22%
-0.54% Impact
Absci Corporation Weight: 6.57% • Perf: -6.32%
-0.42% Impact
Personalis, Inc. Weight: 6.12% • Perf: -3.60%
-0.22% Impact

ETF Profile

Provider ARK
Region World
Country N/A
Sector Health Care
Strategy N/A
Theme Innovation
Distribution Policy Accumulating
Replication Full replication
Sustainable Yes

Aggregate Fundamentals

Weighted average of underlying holdings

Avg P/E Ratio 41.46
Avg Forward P/E -15.48

Growth Analysis

EPS Growth (LY->CY) -10.62%
Revenue Growth (LY->CY) +83.05%
EPS Growth (CY->NY) +61.05%
Revenue Growth (CY->NY) +69.54%
ende